Vericel (VCEL) Depreciation & Amortization (CF) (2010 - 2026)
Vericel (VCEL) reported Depreciation & Amortization (CF) of $3.3 million for Q1 2026, up 21.63% on a YoY basis from $2.7 million in Q1 2025, and up 5.8% sequentially from $3.1 million in Q4 2025.
Vericel (VCEL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $3.3 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 21.63% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $12.1 million (up 77.99% YoY), and the FY2025 full-year result was $11.5 million, up 109.74% from the prior year.
- Depreciation & Amortization (CF) rose to $3.3 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.3 million in Q1 2026 to a low of $873000.0 in Q1 2022.
- A 5-year average of $1.7 million and a median of $1.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) climbed 6.45% in 2023 and surged 122.02% in 2025, its largest moves.
- Tracing VCEL's Depreciation & Amortization (CF) over 5 years: stood at $1.0 million in 2022, then increased by 10.59% to $1.1 million in 2023, then gained by 28.55% to $1.5 million in 2024, then surged by 109.07% to $3.1 million in 2025, then climbed by 5.8% to $3.3 million in 2026.
- Business Quant data shows VCEL's Depreciation & Amortization (CF) at $3.3 million in Q1 2026, $3.1 million in Q4 2025, and $2.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.27 Mn |
| Mar 31, 2026 | 3.27 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.15 Mn |
| Dec 31, 2023 | 1.15 Mn |